Extracellular Vesicle Infusion Therapy for Severe COVID-19
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- ARDS
- COVID-19
- Pneumonia, Viral
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Multi-center, placebo-controlled, randomized clinical trial.Masking: Single (Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 85 years
- Gender
- Both males and females
Description
EXIT COVID-19 is a multi-center, randomized, double-blinded, placebo-controlled trial that will enroll 60 COVID-19 patients with moderate-to-severe ARDS at three research sites across the U.S. The primary efficacy endpoints will be all-cause mortality and median days to recovery.
EXIT COVID-19 is a multi-center, randomized, double-blinded, placebo-controlled trial that will enroll 60 COVID-19 patients with moderate-to-severe ARDS at three research sites across the U.S. The primary efficacy endpoints will be all-cause mortality and median days to recovery.
Tracking Information
- NCT #
- NCT04493242
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon